Walgreens expands vaccination offerings in Florida
DEERFIELD, Ill. — Walgreens on Monday announced the expansion of its vaccination offerings in Florida to include shingles and pneumonia.
“We’ve demonstrated through flu season and other health initiatives the important role Walgreens can play in providing convenient neighborhood access to immunizations and other preventive healthcare services,” stated Terry Gubbins, Walgreens market pharmacy director. “This is an excellent opportunity for our pharmacists to help educate residents about the importance of these vaccinations and collaborate further with our local healthcare providers to help improve immunization rates in our communities.”
The Florida Department of Health recently approved new regulations, giving certified pharmacists the ability to administer both Zostavax — a one-time vaccine that can reduce the risk of shingles in individuals 60 years of age and older — and also pneumococcal vaccine, to help protect against pneumonia.
BioRx acquires Minn. bleeding-disorder pharmacy
CINCINNATI — Specialty pharmacy provider BioRx has acquired another specialty pharmacy provider based in Minnesota, BioRx said Monday.
BioRx, based in Cincinnati and specializing in such bleeding disorders as hemophilia, announced the purchase of Savage, Minn.-based Coagulife, which provides similar services.
"The addition of Coagulife talent and expertise will contribute significantly to our leadership in home hemophilia care," BioRx president and co-founder Phil Rielly said. "We are excited to grow together in delivering outstanding personalized care to the bleeding disorders community."
Jeff Kallberg, who co-founded Coagulife with his brother Daniel in 2004, has hemophilia and speaks around the country about the importance of physical activity for patients with the disorder.
FDA gives priority review to J&J drug
RARITAN, N.J. — The Food and Drug Administration has given priority review to a drug as a treatment for blood-clot disorders, the manufacturer said Monday.
Johnson & Johnson subsidiary Janssen Research & Development said the FDA had given the priority review status to its applications for Xarelto (rivaroxaban) as a treatment for deep-vein thrombosis — a condition in which clots form in one of the large deep veins, usually in the legs — and pulmonary embolism, which occurs when a DVT clot dislodges and is carried to the lung via the heart.
"We are delighted to have received a priority review designation for Xarelto for the treatment of PE and DVT, and also to proven recurrence of these conditions," Janssen R&D VP and cardiovascular franchise medical leader Paul Burton said.
The FDA grants priority review to drugs that offer major advances in care or treat conditions for which there is no adequate therapy. The company announced that it also would withdraw its approval application for Xarelto as a treatment for stent thrombosis in patients with acute coronary syndrome. The drug already is approved for reducing the risk of clots in the legs and lungs of people who have had knee or hip replacement surgery, and to reduce the risk of hemorrhagic and thrombotic strokes and the clots in people with atrial fibrillation not caused by a heart valve problem.